ATOSSA THERAPEUTICS INC. - COMMON STOCK

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

28 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

21 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

20 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

12 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

22 7 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

02 7 2024 15:15:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

28 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

17 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa to Present at the Sidoti Small-Cap Investor Conference

05 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

28 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

15 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

13 5 2024 07:50:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

07 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

29 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

15 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

11 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

09 4 2024 10:59:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

05 4 2024 08:58:53 提供 NetDania Notify

NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK

04 4 2024 10:38:29 提供 NetDania Notify

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

01 4 2024 15:00:00 提供 Nasdaq GlobeNewswire